It has been investigated in patients with systemic lupus erythematosus (SLE), Graves’s disease, ankylosing spondylitis (AS), rheumatoid arthritis (RA), hepatic ischemia, and cardiac ischemic conditions, including acute coronary syndrome (ACS) and MI, with active disease correlating with higher IL-37 levels [8-18, 23-25].In two different studies performed in GBS and MS patients, IL-37 levels were elevated in patients having these disease entities compared to control groups (range: 65 - 130 pg/ml) [19-20]. Here, IL37 is linked to systemic lupus erythematosus.